Profund Advisors LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 9.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,319 shares of the medical research company’s stock after selling 2,651 shares during the quarter. Profund Advisors LLC’s holdings in IQVIA were worth $5,854,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. UMB Bank N A MO bought a new stake in IQVIA during the 4th quarter worth approximately $26,000. Riverview Trust Co bought a new stake in IQVIA during the 1st quarter worth approximately $25,000. Dividend Assets Capital LLC bought a new stake in IQVIA during the 1st quarter worth approximately $27,000. Johnson Financial Group Inc. bought a new position in shares of IQVIA during the 4th quarter worth approximately $34,000. Finally, Catalyst Capital Advisors LLC bought a new position in shares of IQVIA during the 4th quarter worth approximately $38,000. 87.12% of the stock is owned by institutional investors.
IQVIA Price Performance
IQVIA stock traded down $3.48 during midday trading on Wednesday, reaching $241.23. The company’s stock had a trading volume of 16,854 shares, compared to its average volume of 1,039,475. IQVIA Holdings Inc. has a 52 week low of $194.67 and a 52 week high of $285.61. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 2.36. The business has a 50-day moving average price of $220.05 and a 200-day moving average price of $223.67. The stock has a market cap of $44.99 billion, a PE ratio of 40.34, a price-to-earnings-growth ratio of 2.27 and a beta of 1.32.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday. Piper Sandler raised shares of IQVIA from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $231.00 to $255.00 in a research note on Thursday, April 28th. Guggenheim increased their price objective on IQVIA to $246.00 in a report on Friday, July 22nd. SVB Leerink initiated coverage on IQVIA in a report on Friday, July 15th. They issued an “outperform” rating and a $256.00 price objective for the company. Finally, Evercore ISI increased their price objective on IQVIA from $265.00 to $275.00 in a report on Friday, July 22nd. Two research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $274.44.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- Agilent Technologies Proves Its Worth VS Illumina
- Lowe’s Stands Out Amid Q2 Retail Reports
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.